Loading...
NYSE: LLY
Eli Lilly and Company
Healthcare · Drug Manufacturers - General
●S&P 500 since 1970
Market Cap
$870.78B
52w High
$1,133.95
52w Low
$623.78
P/E
40.10
Volume
1.02M
Outstanding Shares
944.82M
Company profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
CEODavid A. Ricks
SectorHealthcare
IndustryDrug Manufacturers - General
Employees47,000
IPO dateJun 1, 1972
Valuation
Forward P/E—
EV/EBITDA35.81
Enterprise value$1T
Stock splits
Oct 16, 19972:1
Dec 21, 19952:1
May 1, 19892:1
Jan 30, 19862:1
Profitability & growth
Revenue growth42.56%
Gross margin83.79%▲3.05%vs FY2024
Operating margin45.56%▲17.26%vs FY2024
ROE77.78%▲4.23%vs FY2024
Analyst consensus
RatingBuy
Target price$1,243.95▲34.97%
32
Buy
9
Hold
3
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Apr 30, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$6.31
$5.60
Q3FY25
ActualEst.
$7.02
$5.69
Q4FY25
ActualEst.
$7.54
$6.91
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$15.56B
$14.7B
Q3FY25
ActualEst.
$17.6B
$16.05B
Q4FY25
ActualEst.
$19.29B
$17.94B
Q1FY26
Next Est.
—